



ASX ANNOUNCEMENT

10 September 2026

## **PKY Appoints Leading NTU Chip Design and AI Expert to Advisory Board**

### **Highlights**

- **Advisory Board established to accelerate Chipforge team build-out and product commercialisation**
- **Inaugural appointment: Professor Anupam Chattopadhyay of Nanyang Technological University (NTU), global leader for Artificial Intelligence**
- **Professor Chattopadhyay's research produced a chip-design tool that was spun out and acquired by CoWare, later acquired by Synopsys, world leader for Artificial Intelligence. He has been integral to the development and testing of Chipforge's technology to date**
- **Anupam joining the Advisory Board complements the recent addition of Sam Weiss as Strategic Advisor**

Pathkey.AI Ltd (ASX: PKY) (Company or PKY) has formed an Advisory Board to support the build-out of its Chipforge team and the commercialisation of the Chipforge platform. This follows the recent acquisition of Chipforge, an AI-native semiconductor design platform, and its integration into the group.

### **About Chipforge**

Chipforge is building a platform that turns a description of what a chip needs to do into verified, working hardware code. The design flow is AI-native: built from the ground up on AI models rather than adding AI features to conventional tools. The platform targets a material reduction in the time and cost of custom chip development.

Once fully developed, the platform will automate custom chip design end to end within a single workflow. AI agents and proprietary models take design intent, expressed as text, images, speech or documents, translate it into hardware design code, run full verification and simulation, and carry the design through synthesis and implementation into an FPGA.

### **Advisory Board and inaugural appointment**

The Advisory Board brings industry and commercialisation expertise to the Chipforge team. Professor Anupam Chattopadhyay is the inaugural appointment. He has been integral to the development and testing of Chipforge's early-stage technology, and his appointment gives the team ongoing access to his expertise as the platform moves toward commercial release.

Anupam Chattopadhyay is a tenured Associate Professor at Nanyang Technological University (NTU), ranked 2nd in the world for Artificial Intelligence by U.S. News & World Report. He holds a PhD from RWTH Aachen in Germany, where his research produced a proprietary chip-design tool spun out as LISATek. LISATek was acquired by CoWare, which was itself later acquired by Synopsys, one of the largest chip design software companies in the world, giving Anupam firsthand experience of a successful trade sale in the semiconductor industry. He brings a rare combination of skills in both chip design and AI, a combination few researchers have, which puts him in a unique position to guide Chipforge product development. His work has been cited more than 10,000 times and covered by outlets including The Economist. In 2025 he won NTU's Innovation and Entrepreneurship Award.

Anupam joins Strategic Advisor, Sam Weiss, as the Company looks to build a formidable team to support the board and management to deliver the PKY objectives. Sam Weiss is a seasoned global executive who served as Chairman of Altium from 2007 until its 2024 acquisition by Renesas for A\$9.1B. From an Australian base Altium became a global leader in PCB design software and built an innovative digital platform for the visualisation of PCB designs.

**Andrew Farnsworth, CEO, commented:** "Anupam has been part of the Chipforge development from the start, so this appointment formalises a relationship that is already delivering. He has built chip design tools that reached the global market and now works at the front edge of AI research. That is exactly the expertise we need as we take Chipforge from technology to product."

**Professor Anupam Chattopadhyay, Advisory Board Member, commented:** "Chipforge sits at the intersection of two fields I've spent my career in chip design and AI. These are critical to developing a genuinely AI-native design platform. Chipforge's proprietary approach is practical and built for real performance, and I'm excited to help this team bring it to a trillion-dollar industry."

The Company intends to appoint further members to the Advisory Board in the coming months. The Advisory Board members will be remunerated by way of issue of performance rights (RSUs) pursuant to the Company's employee incentive scheme.

Authorised for release to ASX by the Board of Pathkey.AI Ltd.

For further information, please contact:

[investors@pathkey.ai](mailto:investors@pathkey.ai)

About Pathkey.AI Ltd

Pathkey.AI Ltd (ASX: PKY) is an Australian technology company focused on developing proprietary AI-powered large language model solutions for data intensive industries. TrialKey is focused on clinical trial design and optimization. Chipforge is developing an AI-powered chip design platform for semiconductor engineering. Both TrialKey and Chipforge platforms are built around an agent-based AI architecture combining large-language-model functionality with neuro-symbolic reasoning to solve complex design optimization problems. In each platform, AI agents generate candidate solutions, evaluate them against defined objectives and iteratively refine them through a structure reflection look using reinforcement driven optimisation.

### About Chipforge

Chipforge is an AI native chip design and verification platform covering FPGA and ASIC targets. It runs an end to end flow from design intent through generated register transfer level code, verification, simulation and sign off. Chipforge Pte. Ltd. is incorporated in Singapore (company number 202556247M) and is part of the PKY Group.

### Forward-looking statements

This announcement contains forward-looking statements, including statements about the timing of the engagement described above, expected milestone completion, and the Company's commercial intentions. Forward-looking statements are based on assumptions and are subject to risks and uncertainties, many of which are outside the Company's control. Actual results may differ materially from those expressed or implied. The Company does not undertake to update forward-looking statements except as required by law.